Now showing items 1-20 of 25

    • Acquired genetic events and NF1 mutations in advanced breast cancer 

      Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, M; Kingston, B; O'Leary, B; Herrera-Abreu, M; Cutts, R; Garcia-Murillas, I; Bye, H; Walker, B; Gonzalez, D; Yuan, L; Jamal, S; Hubank, M; Lopez-Knowles, E; Schuster, E; Dowsett, M; Osin, P; Nerurkar, A; Parton, M; Okines, A; Johnston, S; Ring, A; Turner, N
    • Assessing HER2 Amplification in Plasma cfDNA. 

      Garcia-Murillas, I; Turner, NC (2018-01)
      Digital PCR (dPCR) is a highly accurate method to determine DNA concentration. In dPCR, DNA is portioned into many discrete single entities, and these are analyzed individually for the presence or absence of a target ...
    • Assessment of molecular relapse detection in early-stage breast cancer 

      Garcia-Murillas, I; Chopra, N; Comino-Mendez, I; Beany, M; Tovey, H; Cutts, R; Swift, C; Kriplani, D; Afentakis, M; Hrebien, S; Walsh-Crestani, G; Barry, P; Johnston, S; Ring, A; Bliss, J; Russell, S; Evans, A; Skene, A; Wheatley, D; Dowsett, M; Smith, I; Turner, N
    • Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. 

      Allin, DM; Shaikh, R; Carter, P; Thway, K; Sharabiani, MTA; Gonzales-de-Castro, D; O'Leary, B; Garcia-Murillas, I; Bhide, S; Hubank, M; Harrington, K; Kim, D; Newbold, K (2018-11)
      BACKGROUND:Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in ...
    • Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. 

      O'Leary, B; Hrebien, S; Beaney, M; Fribbens, C; Garcia-Murillas, I; Jiang, J; Li, Y; Huang Bartlett, C; André, F; Loibl, S; Loi, S; Cristofanilli, M; Turner, NC (2019-11)
      BACKGROUND:Circulating tumor DNA (ctDNA) assays are increasingly used for clinical decision-making, but it is unknown how well different assays agree. We aimed to assess the agreement in ctDNA mutation calling between ...
    • Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. 

      Martin, L-A; Ribas, R; Simigdala, N; Schuster, E; Pancholi, S; Tenev, T; Gellert, P; Buluwela, L; Harrod, A; Thornhill, A; Nikitorowicz-Buniak, J; Bhamra, A; Turgeon, M-O; Poulogiannis, G; Gao, Q; Martins, V; Hills, M; Garcia-Murillas, I; Fribbens, C; Patani, N; Li, Z; Sikora, MJ; Turner, N; Zwart, W; Oesterreich, S; Carroll, J; Ali, S; Dowsett, M (2017-11-30)
      Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, ...
    • Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. 

      Weigelt, B; Comino-Méndez, I; de Bruijn, I; Tian, L; Meisel, JL; García-Murillas, I; Fribbens, C; Cutts, R; Martelotto, LG; Ng, CKY; Lim, RS; Selenica, P; Piscuoglio, S; Aghajanian, C; Norton, L; Murali, R; Hyman, DM; Borsu, L; Arcila, ME; Konner, J; Reis-Filho, JS; Greenberg, RA; Robson, ME; Turner, NC (2017-11)
      Purpose: Resistance to platinum-based chemotherapy or PARP inhibition in germline BRCA1 or BRCA2 mutation carriers may occur through somatic reversion mutations or intragenic deletions that restore BRCA1 or BRCA2 function. ...
    • Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016) 

      Herrera-Abreu, MT; Palafox, M; Asghar, U; Rivas, MA; Cutts, RJ; Garcia-Murillas, I; Pearson, A; Guzman, M; Rodriguez, O; Grueso, J; Bellet, M; Cortes, J; Elliott, R; Pancholi, S; Lord, CJ; Baselga, J; Dowsett, M; Martin, L-A; Turner, NC; Serra, V (2016-10)
    • Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. 

      O'Leary, B; Hrebien, S; Morden, JP; Beaney, M; Fribbens, C; Huang, X; Liu, Y; Bartlett, CH; Koehler, M; Cristofanilli, M; Garcia-Murillas, I; Bliss, JM; Turner, NC (2018-03)
      CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA ...
    • Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. 

      Hrebien, S; Citi, V; Garcia-Murillas, I; Cutts, R; Fenwick, K; Kozarewa, I; McEwen, R; Ratnayake, J; Maudsley, R; Carr, TH; de Bruin, EC; Schiavon, G; Oliveira, M; Turner, N (2019-06)
      BACKGROUND:Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for progression-free ...
    • Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. 

      Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J (2015-01)
      Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ...
    • Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. 

      Aarts, M; Sharpe, R; Garcia-Murillas, I; Gevensleben, H; Hurd, MS; Shumway, SD; Toniatti, C; Ashworth, A; Turner, NC (2012-06)
      Inhibition of the protein kinase WEE1 synergizes with chemotherapy in preclinical models and WEE1 inhibitors are being explored as potential cancer therapies. Here, we investigate the mechanism that underlies this synergy. ...
    • The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. 

      O'Leary, B; Cutts, RJ; Liu, Y; Hrebien, S; Huang, X; Fenwick, K; André, F; Loibl, S; Loi, S; Garcia-Murillas, I; Cristofanilli, M; Huang Bartlett, C; Turner, NC (2018-11)
      CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence ...
    • Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. 

      Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, MK; Kingston, B; O'Leary, B; Herrera-Abreu, MT; Cutts, RJ; Garcia-Murillas, I; Bye, H; Walker, BA; Gonzalez De Castro, D; Yuan, L; Jamal, S; Hubank, M; Lopez-Knowles, E; Schuster, EF; Dowsett, M; Osin, P; Nerurkar, A; Parton, M; Okines, AFC; Johnston, SRD; Ring, A; Turner, NC (2020-02)
      PURPOSE:Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential ...
    • Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. 

      Dréan, A; Williamson, CT; Brough, R; Brandsma, I; Menon, M; Konde, A; Garcia-Murillas, I; Pemberton, HN; Frankum, J; Rafiq, R; Badham, N; Campbell, J; Gulati, A; Turner, NC; Pettitt, SJ; Ashworth, A; Lord, CJ (2017-09)
      Although PARP inhibitors target BRCA1- or BRCA2-mutant tumor cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or "revertant" mutations in BRCA1 or BRCA2 ...
    • Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. 

      Lopez-Knowles, E; Pearson, A; Schuster, G; Gellert, P; Ribas, R; Yeo, B; Cutts, R; Buus, R; Garcia-Murillas, I; Haynes, B; Martin, L-A; Smith, I; Turner, N; Dowsett, M (2019-01)
      BACKGROUND:Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS ...
    • Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. 

      Coakley, M; Garcia-Murillas, I; Turner, NC (2019-10)
      Advances in diagnosis and treatment have resulted in a high rate of survival for many patients with early-stage cancers. However, identifying who is at ongoing risk of relapse remains of high priority to direct subsequent ...
    • Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. 

      Garcia-Murillas, I; Schiavon, G; Weigelt, B; Ng, C; Hrebien, S; Cutts, RJ; Cheang, M; Osin, P; Nerurkar, A; Kozarewa, I; Garrido, JA; Dowsett, M; Reis-Filho, JS; Smith, IE; Turner, NC (2015-08)
      The identification of early-stage breast cancer patients at high risk of relapse would allow tailoring of adjuvant therapy approaches. We assessed whether analysis of circulating tumor DNA (ctDNA) in plasma can be used to ...
    • Noninvasive detection of HER2 amplification with plasma DNA digital PCR. 

      Gevensleben, H; Garcia-Murillas, I; Graeser, MK; Schiavon, G; Osin, P; Parton, M; Smith, IE; Ashworth, A; Turner, NC (2013-06)
      PURPOSE:Digital PCR is a highly accurate method of determining DNA concentration. We adapted digital PCR to determine the presence of oncogenic amplification through noninvasive analysis of circulating free plasma DNA and ...
    • Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. 

      Fribbens, C; O'Leary, B; Kilburn, L; Hrebien, S; Garcia-Murillas, I; Beaney, M; Cristofanilli, M; Andre, F; Loi, S; Loibl, S; Jiang, J; Bartlett, CH; Koehler, M; Dowsett, M; Bliss, JM; Johnston, SRD; Turner, NC (2016-09)
      <label>PURPOSE</label>ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized ...